BioMatrix Flex and BioMatrix NeoFlex Coronary Drug Eluting Stent Systems 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Biosensors 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2016-03-02
  • 사례 출판 날짜
    2016-03-02
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: biosensors biomatrix flex and biomatrix neoflex coronary drug eluting stent systems medical device manufacturer, biosensors, has issued a medical device safety alert concerning its biomatrix flex and biomatrix neoflex coronary drug eluting stent systems. the manufacturer is initiating a voluntary recall on certain units of biomatrix flex and biomatrix neoflex coronary drug eluting stent system (des) due to potential balloon burst below the rated burst pressure. the manufacturer discovered during routine lot release testing that several production lots did not meet the balloon rated burst performance specifications. after full investigation, the manufacturer concludes that the compromised balloon performance was caused by certain characteristics in the manufacturing process. according to the manufacturer, the production lots manufactured between october to december 2015 could have been similarly affected. the compromised balloon performance may potentially lead to delay in inflation or deflation of the balloon; or balloon burst when the balloon is inflated above the nominal pressure. this could result in procedural complications and lead to serious deterioration in the patient’s state of health during percutaneous coronary intervention. patients who have already been implanted with an affected device are not impacted by this field safety corrective action. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 2 march 2016.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Biosensors BioMatrix Flex and BioMatrix NeoFlex Coronary Drug Eluting Stent Systems
  • Manufacturer

Manufacturer